Itaconic Acid: Antimicrobial Activities and Biosynthetic Pathways

General Description

Itaconic acid is a potent antimicrobial compound, primarily inhibiting the glyoxylate shunt in bacteria like Mycobacterium tuberculosis and Salmonella enterica, thereby disrupting their ability to utilize alternative carbon sources when glucose is scarce. It functions as a competitive inhibitor of key metabolic enzymes such as isocitrate lyase and methylisocitrate lyase. Moreover, itaconic acid also affects the citramalate cycle by blocking propionyl-CoA carboxylase activity. While it is produced by fungi like Aspergillus itaconicus and mammalian immune cells, some pathogens have evolved detoxification mechanisms to counter itaconic acid's effects, highlighting an ongoing evolutionary struggle between host defenses and bacterial adaptations.

Figure 1. Itaconic acid

Antimicrobial Activities

Role in Inhibiting the Glyoxylate Shunt

Itaconic acid demonstrates significant antimicrobial activity by specifically inhibiting the glyoxylate shunt, a critical metabolic pathway employed by various bacteria for survival during host infection. This shunt allows pathogens, such as Salmonella enterica and Mycobacterium tuberculosis, to utilize alternative carbon sources like fatty acids or cholesterol when glucose is scarce. By interfering with this pathway, itaconic acid disrupts the ability of these pathogens to generate biomass essential for their persistence in host environments, particularly inside macrophages. Itaconic acid functions as a competitive inhibitor of isocitrate lyase, the enzyme responsible for a crucial step in the glyoxylate shunt, effectively blocking the pathogen's ability to bypass key decarboxylation steps of the tricarboxylic acid cycle. ¹

Antimicrobial Properties Against Specific Pathogens

Studies have demonstrated that itaconic acid can inhibit bacterial growth effectively. For instance, research conducted in 2011 indicated that elevated levels of itaconic acid are produced by mammalian immune cells following infection, particularly in the lungs during M. tuberculosis infection. Itaconic acid concentrations of 25 to 50 millimoles per liter resulted in complete inhibition of M. tuberculosis growth in laboratory settings, while lower concentrations significantly impaired the growth of Salmonella enterica. The primary mechanism involves the inhibition of key metabolic enzymes, including isocitrate lyase and methylisocitrate lyase. By disrupting these pathways, itaconic acid prevents pathogen adaptation to alternative carbon sources, making it a potent agent in immune defense against invading pathogens. ¹

Dual Role and Pathogen Adaptation Mechanisms

Interestingly, itaconic acid not only inhibits the glyoxylate shunt but also affects the citramalate cycle by blocking propionyl-CoA carboxylase activity. This broad-spectrum inhibitory action impairs various metabolic pathways in bacteria that lack isocitrate lyase activity, suggesting a broad potential for itaconic acid as an antimicrobial agent. However, some pathogens, such as Yersinia pestis and Pseudomonas aeruginosa, have developed mechanisms to detoxify itaconic acid through the action of specific enzymes, thereby facilitating their survival within host organisms. The identification of these detoxification genes underscores the evolutionary arms race between host defenses and pathogen adaptations. Despite the challenges posed by these adapted bacteria, itaconic acid remains a promising subject of study in the search for novel antimicrobial compounds, especially given its unique modes of action that target critical metabolic pathways in bacterial pathogens. ¹

Biosynthetic Pathways

Discovery and Natural Producers

Itaconic acid, an important compound with various industrial applications, was first identified in 1836 by Baup during the distillation of citric acid. In 1840, Crasso synthesized it from cis-aconitic acid through decarboxylation, ultimately giving it the name itaconic acid, derived as an anagram of cis-aconitic acid. The significant biological discovery related to itaconic acid came in 1931 when it was identified as a metabolite produced in vivo by the fungus Aspergillus itaconicus. This discovery paved the way for recognizing several other natural producers of itaconic acid, including Aspergillus terreus and yeasts such as Candida sp. Notable advancements occurred when researchers, starting in 2011, demonstrated that mammalian immune cells also possess the ability to synthesize itaconic acid, highlighting its broader biological relevance. ²

Biosynthetic Pathways in Aspergillus terreus

The biosynthesis of itaconic acid in Aspergillus terreus involves several metabolic pathways, with considerable interest in understanding its biochemical precursors. Initial hypotheses suggested itaconic acid could originate from cis-aconitic acid, citramalic acid, or 1,2,3-tricarboxypropane. Further research, particularly by Bentley and Thiessen in 1957, established that is likely formed from cis-aconitic acid via decarboxylation catalyzed by the enzyme cis-aconitic acid decarboxylase, encoded by the gene cadA. This process begins with glucose metabolism, leading to the production of pyruvic acid and acetyl-CoA, with aconitase facilitating the conversion of citric acid into the precursor, cis-aconitic acid. The catalytic activity of aconitase and another enzyme, citrate synthase, is crucial for itaconic acid production, as they orchestrate the transformation of substrates into itaconic acid. Factors governing this pathway remain an area of active research, particularly in how oxaloacetic acid influences the regulation of itaconic acid synthesis compared to citric acid production in related fungi. ²

Reference

1. Cordes T, Michelucci A, Hiller K. Itaconic Acid: The Surprising Role of an Industrial Compound as a Mammalian Antimicrobial Metabolite. Annu Rev Nutr. 2015; 35: 451-473.

2. Zhao M, Lu X, Zong H, Li J, Zhuge B. Itaconic acid production in microorganisms. Biotechnol Lett. 2018; 40(3): 455-464.

You may like